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2Department of Pediatrics, Division of Haematology/Oncology, The Hos-
pital for Sick Children, Toronto, ON, Canada; 3Program in Population
Health Sciences, Research Institute, The Hospital for Sick Children,
Toronto, ON, Canada; 4Faculty of Pharmacy, Univeristy of Toronto,
Toronto, ON, Canada.
This study describes the disposition of cyclosporine in 24 children
undergoing HSCT after IV administration and oral administration of
2 different formulations: Neoral and Sandimmune. Whole-blood
samples for cyclosporine measurement were obtained after the ﬁrst IV
cyclosporine dose on day 1 and after the morning dose on each of
the ﬁrst 2 days of oral cyclosporine administration. Neoral was given
on the ﬁrst day of oral cyclosporine administration, and a single dose
of Sandimmune was given in the morning of the second day. Oral
cyclosporine doses were identical and were given on an empty stom-
ach. Cyclosporine concentration-time data were analyzed by noncom-
partmental methods.
A total of 24 children completed the study. After IV administration
of 1.5 0.07 mg/kg, the mean cyclosporine maximum concentration
(Cmax), volume of distribution at steady state, elimination half-life,
clearance, and area under the concentration-versus-time curve (AUC)
were 1103.4  787.71 g/L, 2.6  1.52 L/kg, 4.2  2.49 hours,
0.56  0.255 L/hr/kg, and 2852  1198 g  hr  L1, respectively.
Children took their ﬁrst oral cyclosporine dose on average 29.4 
6.88 days after their ﬁrst IV dose. The mean Cmax observed after
Neoral administration was signiﬁcantly higher than after Sandim-
mune administration (595 349.7 vs 486  363.0 g/L; P  .043),
as was AUC 0–12 hr (3432  1563 vs 3144  1780 g  hr  L1; P 
.022). There was no difference in time to reach Cmax (tmax) between
the formulations. The coefﬁcients of variation in Cmax, tmax, and AUC
were all lower with Neoral than with Sandimmune, but remained
substantial.
The cyclosporine concentration at hour 4 after oral Neoral and
Sandimmune administration exhibited the strongest correlation with
AUC0–12 hr. However, unlike Sandimmune, the trough cyclosporine
concentration after Neoral administration showed the weakest rela-
tionship with AUC (Spearman’s  coefﬁcient  0.568; P  .027).
In children undergoing HSCT, cyclosporine absorption is lower
than that usually seen in children who have undergone solid organ
transplantations. The relationship between cyclosporine concen-
trations during the dosing interval and AUC differs depending on
the oral formulation administered. Thus, Neoral dose adjustment
based on trough concentration may not be appropriate. The link
between pharmacokinetic parameters and clinical outcomes such as
GvHD must be studied further.
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MULTIDISCIPLINARY PROGRAM TO ASSESS UTILIZATION OF VORICON-
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The Departments of Pharmacy and Infectious Diseases (ID) collab-
orated to develop an evidence-based, multidisciplinary voriconazole
surveillance program. Current data suggest that voriconazole is the
preferred treatment for invasive aspergillosis (IA); however, data are
lacking or limited for other indications. Due to the high potential for
misuse, drug expense, and complexity of use, voriconazole use re-
quires ID physician or pharmacist approval. Voriconazole usage
guidelines were developed and implemented collaboratively. Inpa-
tients prescribed voriconazole are identiﬁed in real time by an oncol-
ogy pharmacist, and patient data are recorded in an electronic data-
base. Speciﬁc parameters include indication, results of radiographic
and microbiological studies, prior antifungal therapy, date of voricon-
azole initiation, and plan for therapy. Both pharmacists and physicians
who approve voriconazole have access to the database. The program
helps clinicians determine when appropriate follow-up studies (eg,
chest imaging) should be performed and when or if therapy may be
discontinued. Continuity of care is preserved between inpatient and
outpatient visits. Although not speciﬁcally monitored, the program
may also minimize the development of azole-resistant Candida, pre-
vent superinfection due to fungi resistant to voriconazole, and limit
the potential for adverse effects or drug interactions attributable to
voriconazole therapy. From August 2002 to September 2004, we have
evaluated 17 patients with deﬁnite IA, 17 patients with probable IA,
and 32 patients with possible IA. Five patients received empiric ther-
apy, and 1 patient received voriconazole as prophylaxis. The percent-
ages of patients diagnosed and treated were 80% on the leukemia
service and 17% on the BMT service. Four of the 72 patients were
later diagnosed with mucormycosis while concurrently receiving ther-
apy with voriconazole. Two of these patients had previously docu-
mented IA and had been receiving secondary prophylaxis. The other
2 patients had been treated for possible IA that was diagnosed by abnor-
mal CT scans and pathology subsequently diagnosed mucormycosis.
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Background. Infection is the leading cause of morbidity and mor-
tality among hematopoietic stem cell transplantation recipients. Fun-
gal infection is a particular threat because of difﬁculty in both diag-
nosis and treatment. The frequency of fungal infection is largely
dependent on the mode of transplantation and duration of neutrope-
nia. Although ﬂuconazole prophylaxis in allogeneic and autologous
BMT is well studied, a trial of autologous PBSCT is lacking. Meth-
ods. The Texas Stem Cell Transplant Consortium initiated a phase
III randomized study to evaluate the efﬁcacy of ﬂuconazole for pro-
phylaxis of invasive fungal infections (IFIs) after autologous PBSCT
with an initial planned enrollment of 150 patients. Patients were
randomized to receive either no prophylaxis or ﬂuconazole 400 mg/
day (12 mg/kg if 18 years of age) beginning on the day of stem cell
reinfusion. The prophylaxis phase continued until the postnadir ab-
solute neutrophil count (ANC) reached 1000/L or until the patient
developed an IFI according to EORTC criteria. Primary endpoints
measured included the comparative incidence of proven, probable, or
possible IFI through engraftment and through day 100 posttransplan-
tation and IFI-related mortality through day 100. Overall survival and
the comparative incidence of superﬁcial fungal infection were also
analyzed. Results. Thirty patients have been enrolled to date (16
ﬂuconazole, 14 without prophylaxis). The median stem cell dose
received was 3.5 million CD34 cells/kg for patients randomized to
ﬂuconazole versus 6.2 million CD34 cells/kg for those that did not
receive antifungal prophylaxis. The median duration of neutropenia,
deﬁned as an ANC  1000/L, was 7.5 days, versus 7 days with a
median duration of fever  100.5°F of 2 days and 2.5 days, respec-
tively. Superﬁcial fungal infection developed in none of the ﬂucon-
azole recipients versus 31.3% of patients that received no antifungal
prophylaxis. Additionally, the incidence of proven IFI was 0% in the
ﬂuconazole group versus 18.8% in those that did not receive prophy-
laxis, andmortality due to proven IFI was 0% and 16.7%, respectively.
Although the small numbers do not allow for statistical comparison,
the study was terminated early as a result of the high incidence of IFI
and IFI-related mortality in the patients randomized to receive no
antifungal prophylaxis.Conclusion. Results of this study suggest that
ﬂuconazole prophylaxis should be routinely provided to patients after
autologous PBSCT.
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